Cargando…

Phase I study of dose escalation to dominant intraprostatic lesions using high-dose-rate brachytherapy

PURPOSE: Radiation dose escalation for prostate cancer improves biochemical control but is limited by toxicity. Magnetic resonance spectroscopic imaging (MRSI) can define dominant intraprostatic lesions (DIL). This phase I study evaluated dose escalation to MRSI-defined DIL using high-dose-rate (HDR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chapman, Christopher H, Braunstein, Steve E, Pouliot, Jean, Noworolski, Susan M, Weinberg, Vivian, Cunha, Adam, Kurhanewicz, John, Gottschalk, Alexander R, Roach, Mack III, Hsu, I-Chow
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2018
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6052382/ https://www.ncbi.nlm.nih.gov/pubmed/30038638 http://dx.doi.org/10.5114/jcb.2018.76881

Ejemplares similares

Interactive, multi-modality image registrations for combined MRI/MRSI-planned HDR prostate brachytherapy
por: Reed, Galen, et al.
Publicado: (2011)

Prostate irradiation with focal dose escalation to the intraprostatic dominant nodule: a systematic review
por: Feutren, Thomas, et al.
Publicado: (2018)

Impact of multileaf collimator width on intraprostatic dose painting plans for dominant intraprostatic lesion of prostate cancer
por: Abe, Eisuke, et al.
Publicado: (2010)

Proton versus photon therapy for high-risk prostate cancer with dose escalation of dominant intraprostatic lesions: a preliminary planning study
por: Ong, Ashley Li Kuan, et al.
Publicado: (2023)

Dose differentiated high-dose-rate prostate brachytherapy: a feasibility assessment of MRI-guided dose escalation to dominant intra-prostatic lesions
por: Luminais, Christopher K., et al.
Publicado: (2022)

MRS-guided HDR brachytherapy boost to the dominant intraprostatic lesion in high risk localised prostate cancer
por: Kazi, Aleksandra, et al.
Publicado: (2010)

Cone beam CT-based dose accumulation and analysis of delivered dose to the dominant intraprostatic lesion in primary radiotherapy of prostate cancer
por: Tamihardja, Jörg, et al.
Publicado: (2021)

Measurement of craniocaudal catheter displacement between fractions in computed tomography–based high dose rate brachytherapy of prostate cancer
por: Kim, Yongbok, et al.
Publicado: (2007)

Evaluation of Dose-Painting in the Dominant Intraprostatic Lesions by Radiobiological Parameters using (68)Ga- PSMA PET/CT
por: Bamneshin, Khadijeh, et al.
Publicado: (2022)

Improving plan quality and consistency by standardization of dose constraints in prostate cancer patients treated with CyberKnife
por: Descovich, Martina, et al.
Publicado: (2013)

Dose escalation in oropharyngeal cancer: a comparison of simultaneous integrated boost and brachytherapy boost
por: Embring, Anna, et al.
Publicado: (2023)

Salvage low-dose-rate (125)I partial prostate brachytherapy after dose-escalated external beam radiotherapy
por: Chang, Lynn, et al.
Publicado: (2014)

Prostate specific membrane antigen positron emission tomography for lesion-directed high-dose-rate brachytherapy dose escalation
por: Smith, Christopher W., et al.
Publicado: (2021)

Volumetric and Voxel-Wise Analysis of Dominant Intraprostatic Lesions on Multiparametric MRI
por: Lee, Joon, et al.
Publicado: (2019)

Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir
por: Anwar, Mekhail, et al.
Publicado: (2014)

Dose escalation of a curcuminoid formulation
por: Lao, Christopher D, et al.
Publicado: (2006)

Dose escalation via brachytherapy boost for nasopharyngeal carcinoma in the era of intensity-modulated radiation therapy and combined chemotherapy
por: Chao, Hsing-Lung, et al.
Publicado: (2017)

Pre-plan parameters predict post-implant D(90) ≥ 140 Gy for (125)I permanent prostate implants
por: Alexander, Jes, et al.
Publicado: (2014)

Volumetry of the dominant intraprostatic tumour lesion: intersequence and interobserver differences on multiparametric MRI
por: Harvey, Hugh, et al.
Publicado: (2017)

The Intraprostatic Immune Environment after Stereotactic Body Radiotherapy is Dominated by Myeloid Cells
por: Nickols, Nicholas G., et al.
Publicado: (2020)

Prostate Stereotactic Ablative Radiation Therapy Using Volumetric Modulated Arc Therapy to Dominant Intraprostatic Lesions()
por: Murray, Louise J., et al.
Publicado: (2014)

Individualized Dose-Escalation of HDR Prostate Brachytherapy Implant to Decrease Required External Beam Radiation Dose: A Retrospective Feasibility Study
por: Dahn, Hannah M., et al.
Publicado: (2019)

Conventional dose versus dose escalated radiotherapy including high-dose-rate brachytherapy boost for patients with Gleason score 9–10 clinical localized prostate cancer
por: Yamazaki, Hideya, et al.
Publicado: (2022)

Dosimetric Evaluation of PSMA PET-Delineated Dominant Intraprostatic Lesion Simultaneous Infield Boosts
por: Goodman, Christopher D., et al.
Publicado: (2019)

Feasibility of biology-guided radiotherapy using PSMA-PET to boost to dominant intraprostatic tumour
por: Gaudreault, Mathieu, et al.
Publicado: (2022)

Analysis of outcomes after non-contour-based dose painting of dominant intra-epithelial lesion in intra-operative low-dose rate brachytherapy()
por: Martell, Kevin, et al.
Publicado: (2020)

Results of a Prospective Dose Escalation Study of Linear Accelerator–Based Virtual Brachytherapy (BOOSTER) for Prostate Cancer; Virtual HDR Brachytherapy for Prostate Cancer
por: Eade, Thomas, et al.
Publicado: (2019)

The dose distribution in dominant intraprostatic tumour lesions defined by multiparametric MRI and PSMA PET/CT correlates with the outcome in patients treated with primary radiation therapy for prostate cancer
por: Zamboglou, Constantinos, et al.
Publicado: (2018)

Determination of Intraprostatic and Intratesticular Androgens
por: Šimková, Markéta, et al.
Publicado: (2021)

Dosimetric Uncertainties in Dominant Intraprostatic Lesion Simultaneous Boost Using Intensity Modulated Proton Therapy
por: Zhou, Jun, et al.
Publicado: (2021)

Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer
por: Anwar, Mekhail, et al.
Publicado: (2016)

Efficacy and toxicity of image-guided intensity-modulated radiation therapy combined with dose-escalated brachytherapy for stage IIB cervical cancer
por: Wang, Weiping, et al.
Publicado: (2017)

Intraprostatic Hydatid Cyst: An Unusual Presentation
por: Nouira, Yassine, et al.
Publicado: (2006)

Radiotherapy for Clinically Localized T3b or T4 Very-High-Risk Prostate Cancer-Role of Dose Escalation Using High-Dose-Rate Brachytherapy Boost or High Dose Intensity Modulated Radiotherapy
por: Yamazaki, Hideya, et al.
Publicado: (2021)

Influence of Metal of the Applicator on the Dose Distribution during Brachytherapy
por: Wu, Chin-Hui, et al.
Publicado: (2014)

Presentation of treatment effect in glioblastoma after dose-escalation radiation therapy
por: Cicka, Danielle, et al.
Publicado: (2019)

Need of independent dose verification in brachytherapy
por: Shanta, A
Publicado: (2008)

Low dose rate prostate brachytherapy
por: Stish, Bradley J., et al.
Publicado: (2018)

An automated dose verification software for brachytherapy
por: Wang, Xianliang, et al.
Publicado: (2018)

Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open
por: Sands, Bruce E., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8a8e6d0ggq2cods217l8a93t8q